Toxic serum trough concentrations after administration of nebulized tobramycin.

Abstract

The goal of administering nebulized antibiotics is to provide patients with a high concentration of drug at the infection site with minimal systemic effects. In two studies in which nebulized tobramycin 300 mg twice/day was administered, systemic peak concentrations were below 0.2 and 3.62 microg/ml, and trough concentrations were undetectable, making toxicity from this route of administration negligible. A 19-year-old woman who received a heart transplant was administered tobramycin inhalation solution for Acinetobacter baumanii pneumonia; her serum trough concentrations were found to be toxic (> 2.0 microg/ml). Her risk factors for experiencing these toxic concentrations were renal failure and administration of the drug by positive pressure ventilation. Although nebulized tobramycin is safe under routine circumstances, clinicians must be aware of its potential for toxicity in patients with renal dysfunction or in those receiving positive pressure ventilation.

• Authors: Deborah A Kahler, Kenneth O Schowengerdt, F Jay Fricker, Melissa Mansfield, Gary A Visner, Albert Faro
• Journal: Pharmacotherapy (Pharmacotherapy) Vol. 23 Issue 4 Pg. 543-5 (Apr 2003) ISSN: 0277-0008 [Print] United States
• PMID: 12680485 (Publication Type: Case Reports, Journal Article)

Chemical References

• Tobramycin

Topics

• Administration, Inhalation
• Adult
• Female
• Humans
• Nebulizers and Vaporizers
• Tobramycin (administration & dosage, adverse effects, blood)